tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
The FlyEntrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
4d ago
TRDA
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $17 from $21 at Roth Capital
1M ago
TRDA
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
PremiumRatings
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements
1M ago
TRDA
Entrada Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Entrada Therapeutics Reports Q2 2025 Financial Results
1M ago
TRDA
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
PremiumRatings
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
2M ago
TRDA
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
PremiumThe FlyEntrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
2M ago
TRDA
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
Premium
Company Announcements
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
3M ago
8K
TRDA
Entrada Therapeutics Appoints New Board Member
Premium
Company Announcements
Entrada Therapeutics Appoints New Board Member
4M ago
8K
TRDA
Entrada Therapeutics appoints Radhakrishnan to board of directors
PremiumThe Fly
Entrada Therapeutics appoints Radhakrishnan to board of directors
4M ago
TRDA
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
PremiumRatings
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
4M ago
TRDA
Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
PremiumThe Fly
Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
4M ago
TRDA
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
4M ago
TRDA
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target lowered to $21 from $23 at Roth Capital
4M ago
TRDA
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
Premium
Ratings
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
5M ago
TRDA
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
Premium
The Fly
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)
5M ago
TRDA
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
PremiumRatings
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals
6M ago
TRDA
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
PremiumRatings
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment
6M ago
TRDA
Entrada Therapeutics Gains UK Approval for DMD Study
PremiumCompany Announcements
Entrada Therapeutics Gains UK Approval for DMD Study
6M ago
8K
TRDA
Entrada receives authorization in the UK to initiate ELEVATE-45-201 study
PremiumThe Fly
Entrada receives authorization in the UK to initiate ELEVATE-45-201 study
6M ago
TRDA
Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM
PremiumThe FlyEntrada Therapeutics price target lowered to $23 from $29 at Roth MKM
7M ago
TRDA
Entrada Therapeutics Reports Strong 2024 Financial Results
Premium
Company Announcements
Entrada Therapeutics Reports Strong 2024 Financial Results
7M ago
TRDA
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating
Premium
Ratings
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating
7M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >